From: Aptamers: a novel targeted theranostic platform for pancreatic ductal adenocarcinoma
Targeted therapy | Target | SELEX | Preclinical model | Name | Chemistry | Ref. |
---|---|---|---|---|---|---|
Inhibitor | PAUF | Protein | Xenograft model | P12FR2 | RNA | [50] |
Gemcitabine | EGFR | Protein | In vitro | E07 | RNA | [56] |
AS1411 on gold nanoparticles (AuNS) as inhibitors | Nucleolin | Designed Aptamer | In vitro | AS1411 | DNA | [61] |
Doxorubicin; nanoparticles with Folic acid/AS1411 | Nucleolin | Designed Aptamer | In vitro | AS1411 | DNA | [64] |
Doxorubicin | CD71 | Protein | In vitro | C2-min | RNA | [58] |
5-Fluoro-2′-Deoxyuridine | ALPPL-2 | Cell | In vitro | SQ-2 | RNA | [65] |
Triptolide | Nucleolin | Designed Aptamer | Xenograft model | AS1411 | DNA | [69] |
C/EBPα -saRNA | HPAC | Cell | Xenograft model | P19/P1 | RNA | [55] |
C/EBPα -saRNA | CD71 | Protein | Mouse model of advanced PDAC | TR14 | RNA | [54] |
Gemcitabine or 5-fluorouracil (5-FU) | HPAC | Cell | In vitro | P19 | RNA | [66] |
Inhibitor | Vimentin | Cell | In vitro | P15 | RNA | [53] |
Inhibitor | PD1 | Protein | In vitro | XA-PD1–78 | DNA | [52] |
PD-L1 | XA-PDL1–82 | DNA | ||||
Monomethyl auristatin E (MMAE) | CD71 | Protein | In vitro | Waz | RNA | [70] |
EGFR1 | E07 | |||||
Camptothecin | Tenascin-C | Protein | Xenograft mice | GBI-10 | DNA | [95] |
Gemcitabine | Nucleolin | Designed Aptamer | Xenograft mice | AS1411 | DNA | [63] |
Doxorubicin | CD71 | Cell | In vitro | XQ-2d | DNA | [93] |